The US drug company, Novavax, reviewed its preliminary data and said on Monday that its vaccine appears to be about 90% effective. With the rise of transmissible variants, more vaccine options are critical in the pandemic. The main global vaccine initiative, COVAX, has faced delays as wealthy countries secured the majority of doses.